Brokerages Set Cardlytics, Inc. (NASDAQ:CDLX) Price Target at $6.92

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have been given a consensus recommendation of “Hold” by the seven analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.92.

Several research firms have commented on CDLX. Evercore ISI began coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target for the company. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th.

Insider Buying and Selling

In other Cardlytics news, CFO Alexis Desieno sold 8,854 shares of Cardlytics stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the completion of the sale, the chief financial officer now directly owns 121,976 shares in the company, valued at $447,651.92. This trade represents a 6.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Amit Gupta sold 15,160 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $3.92, for a total transaction of $59,427.20. Following the completion of the sale, the chief executive officer now directly owns 215,494 shares in the company, valued at $844,736.48. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,937 shares of company stock valued at $234,460. 4.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cardlytics

A number of institutional investors have recently modified their holdings of the company. Global Retirement Partners LLC lifted its stake in Cardlytics by 54.7% during the 4th quarter. Global Retirement Partners LLC now owns 19,800 shares of the company’s stock worth $73,000 after acquiring an additional 7,000 shares in the last quarter. Check Capital Management Inc. CA lifted its position in shares of Cardlytics by 11.0% during the fourth quarter. Check Capital Management Inc. CA now owns 56,200 shares of the company’s stock worth $209,000 after purchasing an additional 5,550 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Cardlytics by 38.2% during the fourth quarter. SG Americas Securities LLC now owns 19,490 shares of the company’s stock worth $72,000 after purchasing an additional 5,392 shares in the last quarter. Post Resch Tallon Group Inc. purchased a new position in shares of Cardlytics in the fourth quarter valued at approximately $37,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Cardlytics in the third quarter valued at approximately $82,000. 68.10% of the stock is owned by institutional investors and hedge funds.

Cardlytics Trading Up 3.7 %

Shares of CDLX stock opened at $3.12 on Thursday. The stock has a market capitalization of $158.56 million, a price-to-earnings ratio of -0.51 and a beta of 1.54. Cardlytics has a 12-month low of $2.76 and a 12-month high of $20.52. The stock’s 50-day moving average price is $3.56 and its 200-day moving average price is $4.07. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The company had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. During the same period in the prior year, the firm posted ($0.26) EPS. The firm’s revenue was down 15.1% compared to the same quarter last year. Equities research analysts predict that Cardlytics will post -1.52 EPS for the current fiscal year.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.